Showing results (141-150 of 160) with videos related to
Sort By:
Pageof 16
The Lancet. Infectious Diseases|May 27, 2022
Clinical features and management of human monkeypox: a retrospective observational study in the UKHugh Adler, Susan Gould, Paul Hine, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 11, 2012
The diversity and management of chronic hepatitis B virus infections in the United Kingdom: a wake-up callRichard S Tedder, Alison J Rodger, Lori Fries, et al.Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|September 27, 2018
Two cases of monkeypox imported to the United Kingdom, September 2018Aisling Vaughan, Emma Aarons, John Astbury, et al.The Journal of Antimicrobial Chemotherapy|June 16, 2026
A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infectionSaye H Khoo, Richard FitzGerald, Christopher J Edwards, et al.Clinical Pharmacology and Therapeutics|March 18, 2026
Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib StudyTim Rowland, Richard FitzGerald, Elizabeth Challenger, et al.Journal of Vascular Surgery. Venous and Lymphatic Disorders|July 16, 2021
Surgical resection and graft replacement for primary inferior vena cava leiomyosarcoma: A multicenter experienceMichael Nooromid, Randall De Martino, Francesco Squizzato, et al.Critical Care (London, England)|July 30, 2016
Ebola virus disease and critical illnessAleksandra Leligdowicz, William A Fischer, Timothy M Uyeki, et al.Clinical Pharmacology and Therapeutics|October 26, 2021
An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2Lauren E Walker, Richard FitzGerald, Geoffrey Saunders, et al.Nature Medicine|April 1, 2022
Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adultsBen Killingley, Alex J Mann, Mariya Kalinova, et al.The Lancet. Infectious Diseases|October 22, 2022
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trialSaye H Khoo, Richard FitzGerald, Geoffrey Saunders, et al.Pageof 16